Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rituximab and vemurafenib could challenge frontline chemotherapy for HCL

Key clinical point: A combination of rituximab and vemurafenib offers a high complete remission rate among patients with relapsed or refractory hairy cell leukemia (HCL).

Major finding: Complete remission was achieved in 96% of evaluable patients who received the combination.

Study details: A phase 2 trial involving 31 patients with relapsed or refractory HCL.

Disclosures: Dr. Tiacci reported financial relationships with Roche, AbbVie, and Shire.


Tiacci E et al. EHA Congress, Abstract S104.